Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1.
Yannis LombardiPierre IsnardNathalie ChavarotSophie ChauvetFrank MartinezÉric ThervetDany AnglicheauAlexandre KarrasPublished in: American journal of kidney diseases : the official journal of the National Kidney Foundation (2023)
Primary hyperoxaluria type 1 is a rare cause of kidney failure. Stiripentol, an inhibitor of lactate dehydrogenase A, and lumasiran, a small interfering RNA targeting glycolate oxidase, have been proposed as therapeutic options, but clinical data are scarce, especially in adults and transplanted patients. We describe the case of a 51-year-old patient with a biopsy-proven recurrence of oxalate nephropathy after a kidney-only transplantation. He received stiripentol and lumasiran without adverse events. Fourteen months after transplantation, graft function, serum and urinary oxalate levels have remained stable, and kidney biopsy showed a complete regression of oxalate crystals. Further studies are needed to assess whether this strategy is effective and could replace liver-kidney transplantation.
Keyphrases
- kidney transplantation
- end stage renal disease
- case report
- newly diagnosed
- chronic kidney disease
- ejection fraction
- ultrasound guided
- peritoneal dialysis
- fine needle aspiration
- big data
- electronic health record
- cell therapy
- machine learning
- room temperature
- bone marrow
- mesenchymal stem cells
- artificial intelligence
- case control
- deep learning